These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 26828618)

  • 1. Zoledronic Acid Treatment After Acute Spinal Cord Injury: Results of a Randomized, Placebo-Controlled Pilot Trial.
    Schnitzer TJ; Kim K; Marks J; Yeasted R; Simonian N; Chen D
    PM R; 2016 Sep; 8(9):833-43. PubMed ID: 26828618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
    Cosman F; Eriksen EF; Recknor C; Miller PD; Guañabens N; Kasperk C; Papanastasiou P; Readie A; Rao H; Gasser JA; Bucci-Rechtweg C; Boonen S
    J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with zoledronic acid ameliorates negative geometric changes in the proximal femur following acute spinal cord injury.
    Shapiro J; Smith B; Beck T; Ballard P; Dapthary M; BrintzenhofeSzoc K; Caminis J
    Calcif Tissue Int; 2007 May; 80(5):316-22. PubMed ID: 17417700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of zoledronic acid on bone fusion in osteoporotic patients after lumbar fusion.
    Chen F; Dai Z; Kang Y; Lv G; Keller ET; Jiang Y
    Osteoporos Int; 2016 Apr; 27(4):1469-1476. PubMed ID: 26556733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early treatment with zoledronic acid prevents bone loss at the hip following acute spinal cord injury.
    Bubbear JS; Gall A; Middleton FR; Ferguson-Pell M; Swaminathan R; Keen RW
    Osteoporos Int; 2011 Jan; 22(1):271-9. PubMed ID: 20358358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of zoledronic acid on attenuation of bone loss at the hip and knee following acute traumatic spinal cord injury: a randomized-controlled study.
    Oleson CV; Marino RJ; Formal CS; Modlesky CM; Leiby BE
    Spinal Cord; 2020 Aug; 58(8):921-929. PubMed ID: 32055041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zoledronic acid administration failed to prevent bone loss at the knee in persons with acute spinal cord injury: an observational cohort study.
    Bauman WA; Cirnigliaro CM; La Fountaine MF; Martinez L; Kirshblum SC; Spungen AM
    J Bone Miner Metab; 2015 Jul; 33(4):410-21. PubMed ID: 25158630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of early treatment with zoledronic acid on prevention of bone loss in patients with acute spinal cord injury: a randomized controlled trial.
    Goenka S; Sethi S; Pandey N; Joshi M; Jindal R
    Spinal Cord; 2018 Dec; 56(12):1207-1211. PubMed ID: 30258212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial.
    Anastasilakis AD; Polyzos SA; Gkiomisi A; Bisbinas I; Gerou S; Makras P
    J Clin Endocrinol Metab; 2013 Aug; 98(8):3206-12. PubMed ID: 23788684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Durability and delayed treatment effects of zoledronic acid on bone loss after spinal cord injury: a randomized, controlled trial.
    Edwards WB; Haider IT; Simonian N; Barroso J; Schnitzer TJ
    J Bone Miner Res; 2021 Nov; 36(11):2127-2138. PubMed ID: 34278611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, placebo-controlled trial of intravenous zoledronic acid in the treatment of thalassemia-associated osteopenia.
    Gilfillan CP; Strauss BJ; Rodda CP; Bowden DK; Kean AM; Obaid M; Crawford BA
    Calcif Tissue Int; 2006 Sep; 79(3):138-44. PubMed ID: 16969592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy.
    Israeli RS; Rosenberg SJ; Saltzstein DR; Gottesman JE; Goldstein HR; Hull GW; Tran DN; Warsi GM; Lacerna LV
    Clin Genitourin Cancer; 2007 Mar; 5(4):271-7. PubMed ID: 17553207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.
    Michaelson MD; Kaufman DS; Lee H; McGovern FJ; Kantoff PW; Fallon MA; Finkelstein JS; Smith MR
    J Clin Oncol; 2007 Mar; 25(9):1038-42. PubMed ID: 17369566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zoledronic acid and bone health in older adults with cognitive impairment.
    Churilla BM; Perera S; Greenspan SL; Resnick NM; Kotlarczyk MP
    Osteoporos Int; 2022 Jan; 33(1):293-298. PubMed ID: 34341833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
    Gnant M; Mlineritsch B; Luschin-Ebengreuth G; Kainberger F; Kässmann H; Piswanger-Sölkner JC; Seifert M; Ploner F; Menzel C; Dubsky P; Fitzal F; Bjelic-Radisic V; Steger G; Greil R; Marth C; Kubista E; Samonigg H; Wohlmuth P; Mittlböck M; Jakesz R;
    Lancet Oncol; 2008 Sep; 9(9):840-9. PubMed ID: 18718815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates.
    Miller PD; Pannacciulli N; Brown JP; Czerwinski E; Nedergaard BS; Bolognese MA; Malouf J; Bone HG; Reginster JY; Singer A; Wang C; Wagman RB; Cummings SR
    J Clin Endocrinol Metab; 2016 Aug; 101(8):3163-70. PubMed ID: 27270237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zoledronic acid after spinal cord injury mitigates losses in proximal femoral strength independent of ambulation ability.
    Crack LE; Haider IT; Simonian N; Barroso J; Gabel L; Schnitzer TJ; Edwards WB
    Osteoporos Int; 2023 Sep; 34(9):1637-1645. PubMed ID: 37289320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of parathyroid hormone combined with gait training on bone density and bone architecture in people with chronic spinal cord injury.
    Gordon KE; Wald MJ; Schnitzer TJ
    PM R; 2013 Aug; 5(8):663-71. PubMed ID: 23558091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone turnover and periprosthetic bone loss after cementless total hip arthroplasty can be restored by zoledronic acid: a prospective, randomized, open-label, controlled trial.
    Huang TW; Wang CJ; Shih HN; Chang Y; Huang KC; Peng KT; Lee MS
    BMC Musculoskelet Disord; 2017 May; 18(1):209. PubMed ID: 28532408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.